EICHOR
● Active Not Recruiting
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
Condition: Endometroid Endometrial Cancer · Sponsor: GOG Foundation
About this study
This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective response rate (ORR). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (21)
| City of Hope | Duarte, California, United States | — |
| Mount Sinai Medical Center | Miami Beach, Florida, United States | — |
| AdventHealth Gynecologic Oncology | Orlando, Florida, United States | — |
| Tampa General Hospital | Tampa, Florida, United States | — |
| Moffit Cancer Center at International Plaza | Tampa, Florida, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Moffit Cancer Center at Wesley Chapel | Wesley Chapel, Florida, United States | — |
| Endeavor Health | Evanston, Illinois, United States | — |
| Endeavor Health Clinical Operations, Glenbrook Hospital | Glenview, Illinois, United States | — |
| Endeavor Health Clinical Operations, Highland Park Hospital | Highland Park, Illinois, United States | — |
| Ascension St. Vincent | Indianapolis, Indiana, United States | — |
| Norton Cancer Institute | Louisville, Kentucky, United States | — |
+ 9 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05154487